[Correction of secondary hyperlipidemia in children with diabetes].
At 25 children with insulin dependent diabetes mellitus (IDDM, Type I) in a decompensation stage was estimated efficiency of correction secondary hyperlipidemia. The basic group (n = 11) along with insulinotherapy and a lipotrophic preparation (methionine) accepted probiotic Bifiform Baby in a dose 0.5 g once a day within 10 days; the comparison group (n = 14) received insulin therapy and a lipotrophic preparation. Efficiency of treatment was estimated on dynamics of lipids in serum of blood: triglycerides (TG), the total cholesterol (TH), betalipoproteides (BLP). At patients of the basic group authentic decrease TG, TH, BLP was established; at patients of group of comparison--decrease TH and BLP. Advantage of therapy secondary hyperlipidemia at children with diabetic ketoacidosis with use of Bifiform Baby consists in the elimination of the main infringement of a metabolismus of lipids in the given disease--hypertriglyceridemia.
N V
NV
Gonchar
I Iu
IIu
Mel'nikova
T V
TV
Il'ina
N N
NN
Rudenko
A N
AN
Udalova
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000150:complications* / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D007328:Insulin / Q000008:administration & dosage / Q000627:therapeutic use; D050356:Lipid Metabolism / Q000187:drug effects; D008055:Lipids / Q000097:blood; D008082:Lipotropic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D008715:Methionine / Q000008:administration & dosage / Q000627:therapeutic use*; D019936:Probiotics / Q000008:administration & dosage / Q000627:therapeutic use*; D013812:Therapeutics
D007004:Hypoglycemic Agents; D007328:Insulin; D008055:Lipids; D008082:Lipotropic Agents; D008715:Methionine